Total Payments
$2.3M
2024 Payments
$240,033
Companies
25
Transactions
1,937
Medicare Patients
629
Medicare Billing
$106,908
Payment Breakdown by Category
Other$1.7M (72.3%)
Consulting$428,410 (18.3%)
Travel$150,481 (6.4%)
Food & Beverage$43,790 (1.9%)
Research$24,722 (1.1%)
Education$928.63 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 554 | 69.4% |
| Consulting Fee | $428,410 | 118 | 18.3% |
| Travel and Lodging | $150,481 | 463 | 6.4% |
| Honoraria | $60,200 | 19 | 2.6% |
| Food and Beverage | $43,790 | 769 | 1.9% |
| Unspecified | $24,722 | 4 | 1.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,104 | 1 | 0.3% |
| Education | $928.63 | 9 | 0.0% |
Payments by Type
General
$2.3M
1,933 transactions
Research
$24,722
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $617,333 | 566 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $362,544 | 317 | $0 (2024) |
| Biogen, Inc. | $294,948 | 215 | $0 (2024) |
| Genentech USA, Inc. | $164,816 | 114 | $0 (2024) |
| EMD Serono, Inc. | $137,905 | 146 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $133,707 | 73 | $0 (2024) |
| Celgene Corporation | $107,557 | 132 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $100,527 | 79 | $0 (2024) |
| Horizon Therapeutics plc | $86,948 | 80 | $0 (2023) |
| TG Therapeutics, Inc. | $82,870 | 60 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $240,033 | 190 | TG Therapeutics, Inc. ($59,744) |
| 2023 | $287,227 | 231 | Horizon Therapeutics plc ($49,616) |
| 2022 | $249,964 | 207 | E.R. Squibb & Sons, L.L.C. ($73,980) |
| 2021 | $204,570 | 148 | GENZYME CORPORATION ($41,818) |
| 2020 | $214,446 | 120 | Novartis Pharmaceuticals Corporation ($53,560) |
| 2019 | $424,276 | 377 | GENZYME CORPORATION ($138,485) |
| 2018 | $359,251 | 316 | GENZYME CORPORATION ($172,008) |
| 2017 | $360,173 | 348 | GENZYME CORPORATION ($162,228) |
All Payment Transactions
1,937 individual payment records from CMS Open Payments — Page 1 of 78
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $6,165.00 | General |
| 12/26/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,572.00 | General |
| 12/13/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,036.00 | General |
| 12/13/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $528.74 | General |
| 12/13/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $242.15 | General |
| 12/13/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $108.56 | General |
| 12/12/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,520.00 | General |
| Category: Immunology | ||||||
| 12/09/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,645.00 | General |
| 12/08/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 12/08/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $65.40 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,738.00 | General |
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $62.22 | General |
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $60.46 | General |
| 11/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $153.22 | General |
| 11/18/2024 | EMD Serono Research & Development Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,390.00 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,900.00 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Travel and Lodging | In-kind items and services | $286.31 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Travel and Lodging | Cash or cash equivalent | $273.24 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $94.07 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $16,250 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $3,750 | 1 |
| DEVELOPING A DIGITAL SOLUTION FOR REMOTE ASSESSMENT IN MULTIPLE SCLEROSIS FROM CONCEPT TO SOFTWARE AS A MEDICAL DEVICE | F. Hoffmann-La Roche AG | $2,694 | 1 |
| Satralizumab Treatment in Adults With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Retrospective Case Series | F. Hoffmann-La Roche AG | $2,029 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 210 | 353 | $112,852 | $40,217 |
| 2022 | 5 | 130 | 166 | $60,898 | $23,981 |
| 2021 | 4 | 132 | 179 | $63,529 | $26,726 |
| 2020 | 7 | 157 | 185 | $50,169 | $15,984 |
Total Patients
629
Total Services
883
Medicare Billing
$106,908
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 58 | 150 | $39,831 | $15,487 | 38.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 71 | 92 | $36,214 | $13,098 | 36.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 43 | 45 | $21,870 | $6,485 | 29.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 27 | $8,082 | $2,682 | 33.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 39 | $6,855 | $2,465 | 36.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 69 | 99 | $34,947 | $13,900 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 25 | $6,719 | $2,971 | 44.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $7,283 | $2,674 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $6,416 | $2,280 | 35.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $5,533 | $2,156 | 39.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 68 | 111 | $39,183 | $17,616 | 45.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $8,048 | $3,332 | 41.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 33 | $8,679 | $3,181 | 36.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 19 | 19 | $7,619 | $2,598 | 34.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 50 | 61 | $16,043 | $4,798 | 29.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 23 | 30 | $10,590 | $3,345 | 31.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 26 | 26 | $10,426 | $3,250 | 31.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 24 | 26 | $4,680 | $1,538 | 32.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 11 | 12 | $3,156 | $1,197 | 37.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 18 | $3,114 | $1,148 | 36.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 12 | $2,160 | $707.27 | 32.7% |
About Dr. Robert Shin, M.D
Dr. Robert Shin, M.D is a Neurology healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932124385.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Shin, M.D has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $240,033 received in 2024. These payments were reported across 1,937 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.6M).
As a Medicare-enrolled provider, Shin has provided services to 629 Medicare beneficiaries, totaling 883 services with total Medicare billing of $106,908. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neuro-ophthalmology, Neurology
- Location Charlottesville, VA
- Active Since 07/13/2006
- Last Updated 06/03/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1932124385
Products in Payments
- AUBAGIO (Drug) $269,689
- LEMTRADA (Drug) $243,899
- ZEPOSIA (Drug) $177,639
- TECFIDERA (Drug) $149,198
- GILENYA (Drug) $98,968
- UPLIZNA (Drug) $86,948
- BRIUMVI (Drug) $78,515
- OCREVUS (Biological) $73,118
- TYSABRI (Biological) $71,680
- ACTHAR (Biological) $70,632
- Ocrevus (Biological) $70,409
- MAYZENT (Drug) $66,893
- KESIMPTA (Drug) $64,791
- UPLIZNA (Biological) $39,149
- Ozanimod (Drug) $38,366
- ARZERRA (Drug) $37,903
- SOLIRIS (Biological) $36,918
- Mavenclad (Drug) $33,752
- Soliris (Drug) $32,503
- Mavenclad (Biological) $24,276
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Charlottesville
William Winter, Md, MD
Neurology — Payments: $954,731
Neurology $954,731
Brian Weinshenker, M.d, M.D
Neurology — Payments: $249,928
Neurology $249,928
Nathan Fountain
Neurology — Payments: $48,968
Neurology $48,968
Helen Dainton-Howard, Md, MD
Neurology — Payments: $40,346
Neurology $40,346
Alissa Higinbotham, Md, MD
Neurology — Payments: $35,843
Neurology $35,843
Russell Swerdlow
Neurology — Payments: $31,561
Neurology $31,561